Lumos Pharma to Participate in World Orphan Drug Congress US

AUSTIN, Texas, May 22, 2023 -- Lumos Pharma, Inc. , a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency through Phase 2 clinical... | May 22, 2023

Related Keywords

Texas , United States , Washington , Lisa Miller , Lumos Pharma , John Mckew , Aaron Schuchart , Lumos Pharma Inc , Practices On Patient Group , Nasdaq , World Orphan Drug Congress United States , Patient Focused Drug Development , World Orphan Drug Congress , Pediatric Growth Hormone Deficiency , Chief Scientific Officer , Chief Business Officer , Focused Drug Development , Patient Group , Drug Developer Interaction With , Rare Disease Space , Industry Perspectives , World Orphan Drug , Orphan Drug Designation , Media Contact , Nc Stock Exchange , News , Information , Press Release , Bay , 023 , Lumos , Iopharmaceutical , Company , Dvancing , N , Mural , Herapeutic , Candidate , Or , Idiopathic , Pediatric , Growth , Ormone , Deficiency , Through , Hase , T Lumo Us55028x1090 ,